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Bevirimat is the first in a new class of HIV drugs called
maturation inhibitors that specifically inhibit the last step
in processing of Gag, the conversion of capsid-SP1 (p25)
to capsid (p24). Following bevirimat treatment, viral par-
ticles released from infected cells have abnormal core
structures and are non-infectious. The compound is a
potent inhibitor of HIV-1 replication and retains activity
against drug resistant isolates. It is synergistic with most
approved drugs in vitro. Bevirimat is metabolized by glu-
curonidation and has minimal potential for clinically sig-
nificant drug interactions.
Bevirimat has good oral bioavailability and long half-life
(2.5–3 days) in humans, making it suitable for once-daily
oral dosing. It has been well tolerated in clinical studies,
following administration to more than 300 people for up
to 2 weeks. In a Phase 2a study, 10 days of bevirimat mon-
otherapy at 200 mg/day resulted in >1 log median viral
load reduction. A Phase 2b study was recently initiated
where bevirimat is being studied in combination with
approved drugs in a dose escalation format, in order to
identify optimal dose(s) for Phase 3 clinical trials.
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